Paolo Martelletti

Learn More
At the end of last year, we wrote of the achievements of Lifting The Burden (LTB) in its conduct of the Global Campaign against Headache [1]. In the time since, a notable event has occurred. Earlier in that year, LTB was invited by the World Health Organization (WHO) to apply for admission into Official Relations with it. LTB duly did so and, in January(More)
Migraine is a disabling neurological disease that affects 14.7 % of Europeans. Studies evaluating the economic impact of migraine are complex to conduct adequately and with time become outdated as healthcare systems evolve. This study sought to quantify and compare direct medical costs of chronic migraine (CM) and episodic migraine (EM) in five European(More)
OBJECTIVE To better define the involvement of human leukocyte antigen region (HLA) genes in migraine via an association study of the tumor necrosis factor (TNF) genes, located in the HLA class III region, with migraine with and without aura. BACKGROUND Migraine without aura and migraine with aura are disorders involving multiple factors-environmental and(More)
In September 2003, the World Health Organization (WHO) signed a Memorandum of Understanding that brought into being the Global Campaign against Headache (GC), known as Lifting The Burden. This truly important event for people worldwide affected by headache signalled WHO’s recognition of headache disorders as a global public-health priority. It did not come(More)
From time to time, there is news that is of particular consequence to all people affected by headache. In December 2012, Lancet published the Global Burden of Disease Study 2010 (GBD2010). We wrote then [1]: “Few reports are likely to have more profound meaning for people with headache, or carry greater promise for a better future, than the seven papers(More)
Headache disorders are the most common complaints worldwide. Migraine, tension-type and cluster headaches account for majority of primary headaches and impose a substantial burden on the individual, family or society at large. The burden is immense on workers, women and children in terms of missing work and school days. There are few studies that show(More)
The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in this study was flexible from 155 U to 195 U at the physician’s discretion. Therefore, the objective of this prospective study was to compare the efficacy and safety of OnabotulinumtoxinA 195 U vs.(More)
Segregation analysis indicates that migraine without aura (MWoA) and migraine with aura (MWA) have multifactorial inheritance, but involved genetic and environmental factors are largely unknown. A controlled study was performed to assess the HLA-driven liability to migraine and to verify if the heterogeneity between MWoA and MWA is HLA-linked. Forty-five(More)
The aim of this study was to asses the clinical features, pattern of healthcare and drug utilization of migraine patients attending 10 Italian headache centres (HC). Migraine is underdiagnosed and undertreated everywhere throughout the world, despite its considerable burden. Migraine sufferers often deal with their problem alone using self-prescribing(More)